[Retracted] Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data

Figure 6

The proportion of 21 immune cells affected by the expression of PROK1 and PROK2. PROK1 and PROK2 had 21 TIICs (Th1 cells, NK CD 56bright cells, and Mast cells had significant difference in PROK1 and PROK2).